Pulse Entdecken nav.journalClub Debatten Trends Forschende

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Start Entdecken nav.journalClub Trends

⌘+K

January 13, 2021Open Access

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

Key Points

Key points are not available for this paper at this time.

Abstract

The safety and immunogenicity profiles of Ad26.COV2.S support further development of this vaccine candidate. (Funded by Johnson COV1001 ClinicalTrials.gov number, NCT04436276.).

KI fragen

Like

Bookmark

Share

View Full Paper

KI fragen

Like

Bookmark

Share

View Full Paper

Cite This Study

Sadoff et al. (Wed,) studied this question.

synapsesocial.com/papers/69dc48e08bac30e30e9f57e5 https://doi.org/https://doi.org/10.1056/nejmoa2034201

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | Synapse

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike Variants2006 · 294 citations
2A Novel Coronavirus from Patients with Pneumonia in China, 20192020 · 30,389 citations
3Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)2018 · 342 citations
4Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial2020 · 536 citations
5Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial2020 · 1,293 citations